(Q33492459)

27 July 2017

title

Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer--a randomised study (English)

1 reference

27 July 2017

Halme M

1

1 reference

27 July 2017

Maasilta PK

series ordinal

2

1 reference

27 July 2017

Pyrhönen SO

series ordinal

3

1 reference

27 July 2017

Mattson KV

series ordinal

4

1 reference

27 July 2017

publication date

1 January 1994

1 reference

European Journal of Cancer

27 July 2017

published in

1 reference

27 July 2017

volume

30A

1 reference

27 July 2017

issue

1

1 reference

27 July 2017

page(s)

11-15

1 reference

Treatment of non-small-cell lung cancer

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

The interferons. Mechanisms of action and clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

Interferon receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

Recombinant interferon gamma treatment in non-small cell lung cancer. Antitumour effect and cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

Recombinant interferon A (IFL-rA) therapy of small cell and squamous cell carcinoma of the lung. A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

Combined recombinant human interferon alpha 2 and cytotoxic agents studied in a clonogenic assay

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

Malignant mesothelioma: the antiproliferative effect of cytokine combinations on three human mesothelioma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

Combination chemotherapy and interferon alpha 2b in the treatment of advanced non-small-cell lung cancer. The Italian Lung Cancer Task Force (FONICAP)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

Potentiation of cisplatin by alpha-interferon in advanced non-small cell lung cancer (NSCLC): a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

In vivo effects of combination treatment with recombinant interferon-gamma and -alpha in metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

A new international staging system for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

Natural interferon-alpha alone and in combination with conventional therapies in non-small cell lung cancer. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

Effect of alpha- and gamma-interferon and tumor necrosis factor on colony formation of two human renal tumor xenografts in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

Randomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

The determination of an immunologically active dose of interferon-gamma in patients with melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

Disease stabilization by leukocyte alpha interferon and survival of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

Natural interferon alfa as maintenance therapy for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980009-7

7 January 2021

10.1016/S0959-8049(05)80009-7

Identifiers

DOI

1 reference

27 July 2017

1 reference